The potential of GLP-1 receptor agonists to improve glycemic control, promote weight reduction, and enhance musculoskeletal health presents a promising avenue for reducing the burden of obesity and T2DM in orthopedic practice. This evidence concerns the gene GLP1R and obesity disorder.